Compare MVST & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MVST | ZURA |
|---|---|---|
| Founded | 2006 | 2022 |
| Country | United States | United States |
| Employees | 1908 | 40 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.1M | 455.4M |
| IPO Year | N/A | N/A |
| Metric | MVST | ZURA |
|---|---|---|
| Price | $0.91 | $5.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 4.1M | 1.7M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $24.55 | N/A |
| Revenue Next Year | $17.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.35 |
| 52 Week High | $7.12 | $7.25 |
| Indicator | MVST | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 29.80 | 55.60 |
| Support Level | N/A | $5.17 |
| Resistance Level | $1.38 | $5.88 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 8.32 | 37.50 |
Microvast Holdings Inc develops lithium-ion battery technologies focused on high-performance solutions for commercial and industrial electrification. The Company designs, develops, and manufactures battery components and systems for electric commercial vehicles and energy storage systems (ESS), with applications across buses, trucks, port equipment, and mining machinery. It emphasizes innovation in battery design without relying on legacy technologies and supports platforms such as the IVECO eDaily and various bus models. The Company also provides services, repairs, and warranty and extended warranty support. It operates as a single reportable segment, covering design, development, manufacturing, sales, and leasing of battery systems, and generates the majority of its revenue from Europe.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.